BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

367 related articles for article (PubMed ID: 32425887)

  • 1. GADD45B Transcript Is a Prognostic Marker in Papillary Thyroid Carcinoma Patients Treated With Total Thyroidectomy and Radioiodine Therapy.
    Barros-Filho MC; de Mello JBH; Marchi FA; Pinto CAL; da Silva IC; Damasceno PKF; Soares MBP; Kowalski LP; Rogatto SR
    Front Endocrinol (Lausanne); 2020; 11():269. PubMed ID: 32425887
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor Mutation Burden Predicts Relapse in Papillary Thyroid Carcinoma With Changes in Genes and Immune Microenvironment.
    Guo M; Chen Z; Li Y; Li S; Shen F; Gan X; Feng J; Cai W; Liu Q; Xu B
    Front Endocrinol (Lausanne); 2021; 12():674616. PubMed ID: 34248843
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long non-coding RNA H19 may be a marker for prediction of prognosis in the follow-up of patients with papillary thyroid cancer.
    Jiao X; Lu J; Huang Y; Zhang J; Zhang H; Zhang K
    Cancer Biomark; 2019; 26(2):203-207. PubMed ID: 31403942
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of Estrogen and Progesterone Receptors in Papillary Thyroid Carcinoma in Korea.
    Ahn HY; Song RY; Ahn HS; Kim HS
    Cancer Res Treat; 2021 Oct; 53(4):1204-1212. PubMed ID: 33592140
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BRAF
    Shi C; Cao J; Shi T; Liang M; Ding C; Lv Y; Zhang W; Li C; Gao W; Wu G; Man J
    World J Surg Oncol; 2020 Jun; 18(1):145. PubMed ID: 32593310
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recurrence predictability by various staging systems in 283 patients after thyroidectomy and radioactive iodine treated for papillary thyroid carcinoma.
    Yaniv D; Mizrachi A; Raz R; Tzelnick S; Feinmesser R; Hamzany Y; Vaisbuch Y; Hilly O
    Clin Otolaryngol; 2019 Nov; 44(6):1147-1152. PubMed ID: 31437357
    [No Abstract]   [Full Text] [Related]  

  • 7. A novel RNA sequencing-based risk score model to predict papillary thyroid carcinoma recurrence.
    He J; Tian Z; Yao X; Yao B; Liu Y; Yang J
    Clin Exp Metastasis; 2020 Apr; 37(2):257-267. PubMed ID: 31792675
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Negative Expression of CPSF2 Predicts a Poorer Clinical Outcome in Patients with Papillary Thyroid Carcinoma.
    Sung TY; Kim M; Kim TY; Kim WG; Park Y; Song DE; Park SY; Kwon H; Choi YM; Jang EK; Jeon MJ; Shong YK; Hong SJ; Kim WB
    Thyroid; 2015 Sep; 25(9):1020-5. PubMed ID: 26148673
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transcriptome Analyses Identify a Metabolic Gene Signature Indicative of Dedifferentiation of Papillary Thyroid Cancer.
    Ma B; Jiang H; Wen D; Hu J; Han L; Liu W; Xu W; Shi X; Wei W; Liao T; Wang Y; Lu Z; Wang Y; Ji Q
    J Clin Endocrinol Metab; 2019 Sep; 104(9):3713-3725. PubMed ID: 30942873
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic implication of histological features associated with EHD2 expression in papillary thyroid carcinoma.
    Kim Y; Kim MH; Jeon S; Kim J; Kim C; Bae JS; Jung CK
    PLoS One; 2017; 12(3):e0174737. PubMed ID: 28358874
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low expression of
    Yang L; Zhang X; Zhang J; Liu Y; Ji T; Mou J; Fang X; Wang S; Chen J
    Future Oncol; 2022 Jan; 18(3):333-348. PubMed ID: 34756116
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of tumor size and focality with recurrence/persistence in papillary thyroid cancer patients treated with total thyroidectomy along with radioactive-iodine ablation and TSH suppression.
    Khan M; Syed AA; Khan AI; Hussain SR; Urooj N
    Updates Surg; 2018 Mar; 70(1):121-127. PubMed ID: 28550398
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TERT promoter mutations identify a high-risk group in metastasis-free advanced thyroid carcinoma.
    Bournaud C; Descotes F; Decaussin-Petrucci M; Berthiller J; de la Fouchardière C; Giraudet AL; Bertholon-Gregoire M; Robinson P; Lifante JC; Lopez J; Borson-Chazot F
    Eur J Cancer; 2019 Feb; 108():41-49. PubMed ID: 30648628
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic significance of DNMT3A alterations in Middle Eastern papillary thyroid carcinoma.
    Siraj AK; Pratheeshkumar P; Parvathareddy SK; Bu R; Masoodi T; Iqbal K; Al-Rasheed M; Al-Dayel F; Al-Sobhi SS; Alzahrani AS; Al-Dawish M; Al-Kuraya KS
    Eur J Cancer; 2019 Aug; 117():133-144. PubMed ID: 31280122
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    Wen J; Lin B; Lin L; Chen Y; Wang O
    Aging (Albany NY); 2020 Aug; 12(16):16437-16456. PubMed ID: 32857728
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Integrated analysis identifying new lncRNA markers revealed in ceRNA network for tumor recurrence in papillary thyroid carcinoma and build of nomogram.
    Chen F; Li Z; Deng C; Yan H
    J Cell Biochem; 2019 Dec; 120(12):19673-19683. PubMed ID: 31271223
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictive Value of a Prognostic Model Based on Lymphocyte-to-Monocyte Ratio Before Radioiodine Therapy for Recurrence of Papillary Thyroid Carcinoma.
    Zhou C; Duan D; Liu S
    Technol Cancer Res Treat; 2021; 20():15330338211027910. PubMed ID: 34191658
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BRAF(V600E) Mutation is Associated with Decreased Disease-Free Survival in Papillary Thyroid Cancer.
    Fraser S; Go C; Aniss A; Sidhu S; Delbridge L; Learoyd D; Clifton-Bligh R; Tacon L; Tsang V; Robinson B; Gill AJ; Sywak M
    World J Surg; 2016 Jul; 40(7):1618-24. PubMed ID: 27138882
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Minimal Extrathyroidal Extension in Predicting 1-Year Outcomes: A Longitudinal Multicenter Study of Low-to-Intermediate-Risk Papillary Thyroid Carcinoma (ITCO#4).
    Forleo R; Grani G; Alfò M; Zilioli V; Giubbini R; Zatelli MC; Gagliardi I; Piovesan A; Ragni A; Morelli S; Puxeddu E; Pagano L; Deandrea M; Ceresini G; Torlontano M; Puligheddu B; Antonelli A; Centanni M; Fugazzola L; Spiazzi G; Monti S; Rossetto R; Monzani F; Tallini G; Crescenzi A; Sparano C; Bruno R; Repaci A; Tumino D; Pezzullo L; Lombardi CP; Ferraro Petrillo U; Filetti S; Durante C; Castagna MG
    Thyroid; 2021 Dec; 31(12):1814-1821. PubMed ID: 34541894
    [No Abstract]   [Full Text] [Related]  

  • 20. Long noncoding RNA cancer susceptibility candidate 2 suppresses papillary thyroid carcinoma growth by inactivating the AKT/ERK1/2 signaling pathway.
    Huang F; Zhang Q; Chen W; Zhang H; Lu G; Chen J; Qiu C
    J Cell Biochem; 2019 Jun; 120(6):10380-10390. PubMed ID: 30609134
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.